HOSPITAL LABS REGIONAL REFERENCE LABS
WHAT ARE YOUR PLANS FOR 2015?
If your lab is thinking about how it will reach its goals in 2015, you may be considering new testing opportunities.
- Maintain & Grow Total Revenue by adding new tests
- Increase Revenue per Requisition by performing more tests for each tube sent
- Grow Profitability by offering higher revenue tests
Doing the same thing as last year will not accomplish your goals.
Try offering a new test that your competitors don’t have to help you grow your numbers for 2015.
JUST ANNOUNCED: LUNG CANCER SCREENING TO BE COVERED BY MEDICARE AND COMMERCIAL PAYERS STARTING IN 2015
In November 2014, Medicare announced they will begin covering annual lung cancer screenings starting in 2015. Commercial labs are already required to cover these screenings as mandated by the Affordable Care Act. Physicians are going to face large numbers of patients that will require and demand testing for lung cancer starting this year.
ALL PRIMARY CARE AND INTERNAL MEDICINE PHYSICIANS WILL NEED TO TEST FOR LUNG CANCER
A SIMPLE BLOOD TEST USING A SINGLE SST – SENT OUT TO OUR LAB
PAULA’s Test is blood test which can help detect lung cancer at an early stage, while it can still be cured with surgery. The test can help detect if someone already has lung cancer, before there are any symptoms. It uses a blood sample to analyze a handful of protein biomarkers associated with the presence of a lung cancer tumor. The test is NOT a genetic test. It does not test for predisposition for lung cancer, it tests for the possible presence of lung cancer at the time of testing.
Annual lung cancer screening of smokers and former smokers is now recommended by major medical organizations including the American Lung Association, the American Society of Clinical Oncology, the American College of Chest Physicians, and the American Cancer Society. In spite of this broad acceptance of the benefits of screening, compliance with the new guidelines is very low.
If lung cancer is detected early it can often be cured with surgery. When found late, 5 year survival rates are 5% or less. Genesys Biolabs offers a blood test to aid in the early detection of lung cancer. When used in high risk, asymptomatic patients, PAULA’s Test can help you measure a patient’s risk of having undiagnosed lung cancer. Recommended for patients who are not undergoing yearly CT screening, PAULA’s Test can help identify patients with an elevated risk of having lung cancer so those patients can be followed up with CT screening.
Lung cancer causes more deaths than breast, prostate and colorectal cancer combined. Approximately 90% of lung cancers are caused by smoking. Heavy smokers and former smokers can have up to a 1 in 7 lifetime risk of developing lung cancer.
If diagnosed early enough to be surgically removed before it spreads the survival rate for lung cancer can approach 80%. But fewer than 5% of patients with lung cancer are diagnosed at this early stage. Most cases of lung cancer will be diagnosed only after presenting symptoms; when the cancer has advanced to the later stages and curative surgery is no longer an option.
HOW LABS CAN START TESTING FOR LUNG CANCER
If you are not currently screening your high risk patients with annual CT’s, your odds of finding a patient with early stage lung cancer are very low. By using PAULA’s Test, you can improve those odds and select those patients at the highest risk . Using PAULA’s test in conjunction with CT physicians can improve the effectiveness of CT and make early detection of lung cancer a realistic proposition.
PATIENTS FOR PAULA’s TEST
Smokers and Ex-smokers, ages 50 and older can be tested. The test is recommended for patients that meet the following criteria:
- Ages 50 and older, and
- Have smoked an amount that equals an average of 1 pack per day for at least 20 years, or the equivalent amount of exposure, and
- Ex-smokers who have quit within the past 15 years.
The test is only recommended for patients who are not currently symptomatic for lung cancer or who are not already receiving annual CT scans for lung cancer.